Enerisant

Enerisant
Clinical data
Other names	TS-091
Routes of; administration	By mouth
Pharmacokinetic data
Protein binding	31.0–31.7%
Elimination half-life	8 hours
Excretion	Kidney (64.5–89.9%)
Identifiers
	IUPAC name [1-[4-[3-[(2R)-2-methylpyrrolidin-1-yl]propoxy]phenyl]pyrazol-4-yl]-morpholin-4-ylmethanone;
CAS Number	1152747-82-4;
PubChem CID	42601503;
IUPHAR/BPS	11293;
ChemSpider	44208825;
UNII	E2Y97PQY3A;
Chemical and physical data
Formula	C22H30N4O3
Molar mass	398.507 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)N3C=C(C=N3)C(=O)N4CCOCC4;
	InChI InChI=1S/C22H30N4O3/c1-18-4-2-9-24(18)10-3-13-29-21-7-5-20(6-8-21)26-17-19(16-23-26)22(27)25-11-14-28-15-12-25/h5-8,16-18H,2-4,9-15H2,1H3/t18-/m1/s1; Key:IABXVJILZYNSTM-GOSISDBHSA-N;

Enerisant is an experimental drug under investigation as a potential treatment for narcolepsy. It is a member of the histamine H₃ receptor antagonist/inverse agonist class of medications.

Clinical data

Other names	TS-091
Routes of administration	By mouth
Pharmacokinetic data
Protein binding	31.0–31.7%
Elimination half-life	8 hours
Excretion	Kidney (64.5–89.9%)
Identifiers
IUPAC name [1-[4-[3-[(2R)-2-methylpyrrolidin-1-yl]propoxy]phenyl]pyrazol-4-yl]-morpholin-4-ylmethanone
CAS Number	1152747-82-4
PubChem CID	42601503
IUPHAR/BPS	11293
ChemSpider	44208825
UNII	E2Y97PQY3A
Chemical and physical data
Formula	C₂₂H₃₀N₄O₃
Molar mass	398.507 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)N3C=C(C=N3)C(=O)N4CCOCC4
InChI InChI=1S/C22H30N4O3/c1-18-4-2-9-24(18)10-3-13-29-21-7-5-20(6-8-21)26-17-19(16-23-26)22(27)25-11-14-28-15-12-25/h5-8,16-18H,2-4,9-15H2,1H3/t18-/m1/s1 Key:IABXVJILZYNSTM-GOSISDBHSA-N